Immunocore

Yahoo Finance • last month

Jefferies assumes coverage on Immunocore stock with Buy rating, $48 target

Investing.com - Jefferies has assumed coverage on Immunocore Holdings (NASDAQ:IMCR) with a Buy rating and a $48.00 price target, according to a research note released Monday. The company, currently trading at $32.93, shows strong financial... Full story

Yahoo Finance • 2 months ago

Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growth

Immunocore Holdings PLC (NASDAQ:IMCR [https://www.chartmill.com/stock/quote/IMCR]) reported its second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) figures that exceeded analyst expectations. The company... Full story

Yahoo Finance • 2 months ago

Immunocore reports second quarter financial results and provides a business update

KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Pha... Full story

Yahoo Finance • 2 months ago

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative i... Full story

Yahoo Finance • 2 months ago

Immunocore stock price target raised to $36 from $33 at Mizuho

Investing.com - Mizuho has raised its price target on Immunocore Holdings (NASDAQ:IMCR) to $36.00 from $33.00 while maintaining a Neutral rating on the stock. According to InvestingPro data, the company maintains a "GREAT" financial health... Full story

Yahoo Finance • 3 months ago

Immunocore's SWOT analysis: stock outlook amid pipeline progress, market challenges

Immunocore Holdings plc (NASDAQ:IMCR), a biotechnology company specializing in T-cell receptor-based therapeutics for cancer and infectious diseases, has been navigating a complex landscape of clinical advancements and market challenges. W... Full story

Yahoo Finance • 7 months ago

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active... Full story

Yahoo Finance • 7 months ago

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative i... Full story

Yahoo Finance • 7 months ago

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma ind... Full story

Yahoo Finance • 12 months ago

Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other Worst 52-Week Low Sto... Full story

Yahoo Finance • 12 months ago

Immunocore Holdings plc (IMCR) Hits 52-Week Low Despite 34% Surge in KIMMTRAK Sales

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other worst 52-week low stock... Full story

Yahoo Finance • last year

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore Holdings plc Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PR... Full story

Yahoo Finance • 2 years ago

An Intrinsic Calculation For Immunocore Holdings plc (NASDAQ:IMCR) Suggests It's 50% Undervalued

Key Insights The projected fair value for Immunocore Holdings is US$136 based on 2 Stage Free Cash Flow to Equity Immunocore Holdings is estimated to be 50% undervalued based on current share price of US$68.32 Analyst price target for IMC... Full story

Yahoo Finance • 2 years ago

Levicept Appoints Eliot Forster as CEO

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology compan... Full story

Yahoo Finance • 2 years ago

11 Best Undervalued UK Stocks To Buy Now

In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest eco... Full story

Yahoo Finance • 2 years ago

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets with continued reimbursement expansion gl... Full story

Yahoo Finance • 2 years ago

Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific... Full story

Yahoo Finance • 2 years ago

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untre... Full story

Yahoo Finance • 2 years ago

Immunocore announces upcoming presentation and posters at ESMO 2023

Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session (... Full story

Yahoo Finance • 2 years ago

10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts

In this article, we will take a look at the 10 stocks receiving a massive vote of approval from Wall Street analysts. If you want to see some more stocks on the list, go directly to 5 Stocks Receiving a Massive Vote of Approval From Wall S... Full story